Phase 2 N=42 Trikafta in Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Percent Predicted Forced Expiratory Volume in One Second (FEV1) Among Participants With Evidence of Partial Function — 74.8; 76 percent of predicted FEV1
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=125 Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia
Insomnia
Primary: Percentage of Time Spent in the Combination of Slow Wave Sleep (SWS) and Rapid Eye Movement (REM) Sleep — 43.0; 41.8 Percentage of total sleep time — p=0.0350
Phase 2 N=18 A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
Breast Cancer · Breast Cancer Stage · Breast Cancer Stage I
Primary: Wound Surface Area Reduction of Radiation Dermatitis Grade 2-3 Wound Size From Baseline to Day 14 (+/- 3 Days) — 10.3; 25.3; 0.5; 4.1 cm^2
Phase 2 N=4 A Study of BAX 888 in Male Adults With Severe Hemophilia A
Hemophilia A
Primary: Number of Participants With BAX 888-Related Adverse Events (AEs) — 2; 2 Participants
Phase 2 N=38 Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Number of Participants Alive With and Without Disease Progression — 4; 6; 28 Participants
Phase 2 N=46 Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Stringent Complete Response (sCR) — 17 Participants
Phase 2 N=147 A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
Binge-Eating Disorder
Primary: Change From Baseline in Number of Binge Eating Days Per Week — -3.44; -3.07; -3.01 binge eating days per week — p=0.1893
Phase 2 N=328 A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Glabellar Lines
Primary: Percentage of Participants With Achievement of ≥ 1-grade Improvement From Baseline as Rated by Investigator Using the Clinician Glabellar Lines Scale. — 17.8; 95.6…
Phase 2 N=6 An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease
Batten Disease
Primary: Number of Treatment-emergent Adverse Events. — 6 Participants
Phase 2 N=39 Intraoperative Nitrous Oxide and Postoperative Pain for Patients With Current Opioid Treatment
Chronic Pain
Primary: Post-operative Morphine Consumption — 54.6; 44.8 mg — p=0.5
Phase 2 N=170 A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults
Influenza Prevention
Primary: Number of Participants With Solicited Local Adverse Events (AEs) Within 7 Days After Vaccination 1 — 5; 12; 3; 13 Participants
Phase 2 N=120 Anti-viral Therapy in Alzheimer's Disease
Alzheimer Disease · Herpes Simplex 1 · Herpes Simplex 2
Primary: Alzheimer's Disease Assessment Scale - Cognition (ADAS-COG11, Modified Version) Score — 20.6; 19.2; 30.2; 25.3 score on a scale — p=<0.05
Phase 2 N=90 Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery
Postoperative Pain · Cancer
Primary: Proportion of Patients With Major Post-operative Pain at Mobilization Following Lung Surgery by Posterolateral Thoracotomy — 4; 3 Participants — p=0.99
Phase 2 N=189 A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
Huntington's Disease
Primary: Change From Baseline in the SDMT — 2.0; 0.8 score on a scale — p=0.1675
Phase 2 N=300 Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens
Healthy
Primary: Carcinogen Detoxification of Metabolites in Urine. — 7.26; 6.11; 3052.39; 1843.29 ng/mL